US Stock Market Move | Most of the Chinese pharmaceutical stocks rose, BEIGENE (ONC.US) by over 9%
Most Chinese pharmaceutical stocks are up, as of press time, BeiGene's shares surged more than 9%.
On Tuesday, most of the Chinese pharmaceutical stocks rose. As of press time, BeiGene (ONC.US) rose by over 9%, HutchMed (HCM.US) rose by over 4%; and Zai Lab (ZLAB.US) dipped slightly by 0.08%. In terms of news, BeiGene CEO John Oyler mentioned that, according to US Generally Accepted Accounting Principles, the company is expected to achieve a positive operating profit for the full year of 2025 (meaning that operating income will exceed the sum of operating costs, sales expenses, management expenses, and research and development expenses).
Related Articles
CHABAIDAO (02555) rises more than 3% in the afternoon, with double-digit revenue and profit growth in 2025.
.png)
COSMO LADY (02298) earned 123 million HKD in 2025, with a dividend of 1.6 cents.
LONGFOR GROUP (00960) announces annual performance with revenue of 97.309 billion yuan and three consecutive years of positive operating cash flow after covering capital expenditure.
CHABAIDAO (02555) rises more than 3% in the afternoon, with double-digit revenue and profit growth in 2025.
COSMO LADY (02298) earned 123 million HKD in 2025, with a dividend of 1.6 cents.
LONGFOR GROUP (00960) announces annual performance with revenue of 97.309 billion yuan and three consecutive years of positive operating cash flow after covering capital expenditure.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
